Bolivia has registered Sputnik V vaccine based on Russian clinical trial data
Sputnik V has been registered under the emergency use authorization procedure
Moscow, January 6, 2021 –
The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces the registration of the Russian Sputnik V vaccine against coronavirus by State Agency for Medicines and Health Technologies (Agencia Estatal De Medicamentos Y Tecnologías En Salud, AGEMED) of the Plurinational State of Bolivia.
The vaccine was registered under the emergency use authorization procedure and was approved by AGEMED based on the results of Phase III clinical trials in Russia, without additional trials in Bolivia. Sputnik V was registered by Argentina’s regulator ANMAT under the same procedure on December 23, 2020.
To improve the performance of our website, show the most relevant news products and targeted advertising, we collect technical impersonal information about you, including through the tools of our partners. You can find a detailed description of how we use your data in our Privacy Policy. For a detailed description of the technologies, please see the Cookie and Automatic Logging Policy.
By clicking on the Accept & Close button, you provide your explicit consent to the processing of your data to achieve the above goal.
You can withdraw your consent using the method specified in the Privacy Policy.
Accept & Close
Sputnik International